MedTrace Logo

Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Risk of COVID_19

NCT05398731 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2022-06-07

No results posted yet for this study

Summary

1. To determine the risk of COVID -19 in patients who use ACEI and ARBS
2. To determine the Effect of ACEI and ARBS on COVID -19 infection .
3. To determine the Severity of COVID -19 in patients who use ACEI and ARBS .

Conditions

Interventions

OTHER

Covid_19

Duration, type of response, and the time period between the begining of drug and the emergence of symptoms of COVID-19

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Hanan M Adawy Nafeh, PhD · Assiut University

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-30
Primary Completion
2023-03-31
Completion
2023-05-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05398731 on ClinicalTrials.gov